arrow
S

Scott E. Woodman

genomic medicine
H指数:59
被引数:3.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial

在抗PD-L1治疗的 Newly Diagnosed Glioblastoma 患者队列中,总体生存率的改善与特定的免疫、突变和肠道微生物组特征相关:一项单臂前瞻性I/II期试验

2025-04-270
OA
Chromosome 3 copy number loss alone drives tumor evolution to aggressive disease in uveal melanoma
2024-03-220
PRE
Chromosome 3 dosage-loss informs on the unique biology underlying ultra high-risk uveal melanoma
2024-03-220
PRE
Advanced preclinical modeling reveals unique monosomy 3 associated biology in late-stage uveal melanoma
2023-04-040
PRE
Deploying spatial transcriptomics to inform intratumoral heterogeneity in late-stage uveal melanoma leveraging advanced preclinical modeling and clinical samples
2023-04-040
PRE
Biomarker analysis: Multi-omics elucidation of Cohort 1 from a phase II study of a triple combination of Atezolizumab plus cobimetinib plus eribulin in patients with metastatic inflammatory breast cancer
2023-03-012
PRE
Multi-modal molecular programs regulate melanoma cell state
2022-07-0911
OAAI
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma
2021-11-069
OA
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

联合PD-L1 (阿特珠单抗) 和VEGF (贝伐单抗) 阻断治疗晚期恶性腹膜间皮瘤的疗效、安全性和生物标志物分析

2021-07-1448
OA
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

肠道菌群特征与联合CTLA-4和PD-1阻断的毒性有关

2021-07-08251
OAAI